Portal de investigación
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- de Miguel-Perez D
- Russo A
- Arrieta O
- Ak M
- Barron F
- Gunasekaran M
- Mamindla P
- Lara-Mejia L
- Peterson CB
- Er ME
- Peddagangireddy V
- Buemi F
- Cooper B
- Manca P
- Lapidus RG
- Hsia R.-C.
- Naing A
- Kaushal S
- Hirsch FR
- Mack PC
- Serrano MJ
- Adamo V
- Colen RR
- Rolfo C
Grupos de investigación
Resumen
Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs. © 2022, The Author(s).
© 2022. The Author(s).
Datos de la publicación
- ISSN/ISSNe:
- 0392-9078, 1756-9966
- Tipo:
- Article
- Páginas:
- 186-186
- Enlace a otro recurso:
- www.scopus.com
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH BioMed Central Ltd
Citas Recibidas en Web of Science: 32
Citas Recibidas en Scopus: 56
Documentos
- No hay documentos
Filiaciones
Keywords
- B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Extracellular Vesicles; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Prospective Studies; Retrospective Studies; docetaxel; immune checkpoint inhibitor; nivolumab; pembrolizumab; programmed death 1 ligand 1; tumor marker; programmed death 1 ligand 1; adult; advanced cancer; antigen expression; Article; cancer immunotherapy; cancer patient; cancer survival; cohort analysis; controlled study; disease marker; drug response; dynamics; exosome; female; human; human tissue; image analysis; major clinical study; male; metastasis; non small cell lung cancer; overall survival; plasma; prediction; progression free survival; prospective study; protein expression; radiomics; retrospective study; sensitivity and specificity; x-ray computed tomography; drug therapy; lung tumor; metabolism; non small cell lung cancer; pathology
Proyectos asociados
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Citar la publicación
de Miguel D,Russo A,Arrieta O,Ak M,Barron F,Gunasekaran M,Mamindla P,Lara L,Peterson CB,Er ME,Peddagangireddy V,Buemi F,Cooper B,Manca P,Lapidus RG,Hsia R-C,Cardona AF,Naing A,Kaushal S,Hirsch FR,Mack PC,Serrano MJ,Adamo V,Colen RR,Rolfo C. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022. 41. (1):p. 186-186. IF:11,300. (1).